SARS-CoV-2 infections are exacting a horrific burden of morbidity and mortality around the world. While we have much to learn about the virus and COVID-19, the disease it causes, the most likely way to control and possibly eliminate COVID-19 is a vaccine for SARS-CoV-2. Typically successful vaccines need adjuvants to increase the immunogenicity of their response. A strong response will be especially important for COVID-19 as the virus particle has multiple spikes (S- proteins) that are the target of the majority of vaccines under development. This project would leverage ongoing efforts to discover novel small molecule immunomodulators produced by members of the human gut microbiota to discover and develop adjuvants. The small molecule immunomodulators discovered in this project appear to have excellent prospects as adjuvants as they both boost and resolve immune responses. The two Specific Aims, which can be prosecuted simultaneously, deal with further molecular and mechanistic analysis of a promising set of lipids produced by Akkermansia muciniphila, a recently recognized member of the human gut microbiota whose abundance is highly correlated with outcomes in both type 2 diabetes (T2D), and PD-1 cancer immunotherapy. Work in Specific Aim 1 will identify the structure-activity relations for the lipids where activity is release of inflammatory cytokines like TNF? and IL-6. The lipids signal through TLR2, and we would establish whether heterodimerization with TLR-1 or TLR-6 is required for activity and the need for adaptor proteins like MAL/TIRAP and MyD88. We will also assess the downstream T cell polarization following mBMDC activation.
In Specific Aim 2 we will replicate the studies that led to the initial identification of the A. mucinophila lipids on other members of the human gut microbiota, especially those that correlate or anti-correlate strongly with inflammatory diseases. In sum, the project will characterize the immune signaling pathways triggered by bacterial TLR2 agonists to identify adjuvant candidates that may increase the therapeutic efficacy of soon to be developed COVID-19 vaccines.
COVID-19 is a devastating and continuing public health threat, and our best chance for controlling the virus that causes it, SARS-CoV-2, is an effective vaccine or vaccines. Vaccines typically need adjuvants to increase their effectiveness to therapeutically useful levels. This project will identify new potential adjuvants produced by bacteria found in the human gut microbiome to be used in conjunction with newly developed SARS-CoV-2 vaccines.
| Bakker, Olivier B; Aguirre-Gamboa, Raul; Sanna, Serena et al. (2018) Integration of multi-omics data and deep phenotyping enables prediction of cytokine responses. Nat Immunol 19:776-786 |
| Kretsch, Ashley M; Morgan, Gina L; Tyrrell, Jillian et al. (2018) Discovery of (Dihydro)pyrazine N-Oxides via Genome Mining in Pseudomonas. Org Lett 20:4791-4795 |
| Schirmer, Melanie; Denson, Lee; Vlamakis, Hera et al. (2018) Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course. Cell Host Microbe 24:600-610.e4 |
| Graham, Daniel B; Luo, Chengwei; O'Connell, Daniel J et al. (2018) Antigen discovery and specification of immunodominance hierarchies for MHCII-restricted epitopes. Nat Med 24:1762-1772 |
| Coutinho, Bruna G; Mevers, Emily; Schaefer, Amy L et al. (2018) A plant-responsive bacterial-signaling system senses an ethanolamine derivative. Proc Natl Acad Sci U S A 115:9785-9790 |
